This is a 12-week randomized, placebo-controlled trial of N-acetylcysteine for cannabis use
disorder (CUD) in youth (N=192). Participants will be randomized to double-blind NAC or PBO,
yielding two equally-allocated treatment groups. All participants will receive brief weekly
cannabis cessation counseling and medication management. The primary efficacy outcome will be
the proportion of negative urine cannabinoid tests during the 12-week active treatment,
compared between groups.